Want to see JSPR full AI Analyst Report?
Top Page
Jasper Therapeutics
(NASDAQ:JSPR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.47
▼(-34.44% Downside)
Action:Reiterated
Date:10/15/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and significant cash burn with diminished equity) and bearish technicals (price below key moving averages with negative MACD). Offsetting these, corporate events are positive—most notably the $132M PIPE and acquisition-driven pipeline focus that extends operating runway—providing some support despite limited valuation anchors from a negative P/E and no dividend.
Positive Factors
Phase 2 renal pipeline progress
Completing enrollment in the IgA nephropathy cohort provides a defined clinical development milestone, while adding a focal segmental glomerulosclerosis cohort broadens testing across complement-mediated kidney diseases. This expands the potential application of vensobafusp alfa and supports pipeline progress over the next several quarters.
Negative Factors
Pre-commercial business model
Jasper remains pre-commercial, with no product revenue to fund research, clinical development or corporate expenses. Continued losses mean the business has not yet demonstrated operating leverage, and future financial performance remains dependent on clinical progress, regulatory approval and eventual commercialization or partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2 renal pipeline progress
Completing enrollment in the IgA nephropathy cohort provides a defined clinical development milestone, while adding a focal segmental glomerulosclerosis cohort broadens testing across complement-mediated kidney diseases. This expands the potential application of vensobafusp alfa and supports pipeline progress over the next several quarters.
Read all positive factors
Jasper Therapeutics (JSPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.63M
Dividend YieldN/A
Average Volume (3M)361.75K
Price to Earnings (P/E)―
Beta (1Y)2.68
Revenue GrowthN/A
EPS Growth73.74%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.59
Shares Outstanding33,274,563
10 Day Avg. Volume376,086
30 Day Avg. Volume361,752
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-220.02
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$7.50Price Target Upside941.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$6.00M
Jasper Therapeutics Business Overview & Revenue Model
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed t...
How the Company Makes Money
As a clinical-stage biotechnology company, Jasper Therapeutics does not have broadly available evidence of recurring product sales from commercialized drugs; as such, revenue from product sales is null. Its funding and any reported revenue are typ...
Jasper Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -21.00K | -1.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -31.21M | -74.75M | -69.90M | -63.36M | -36.71M | -30.26M |
| Net Income | -31.77M | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
Balance Sheet | ||||||
| Total Assets | 11.80M | 35.78M | 79.90M | 94.89M | 48.36M | 93.65M |
| Cash, Cash Equivalents and Short-Term Investments | 7.31M | 28.69M | 71.64M | 86.89M | 38.25M | 84.70M |
| Total Debt | 270.00K | 1.24M | 1.81M | 2.79M | 3.65M | 2.88M |
| Total Liabilities | 10.39M | 31.63M | 18.23M | 16.45M | 12.37M | 24.14M |
| Stockholders Equity | 1.41M | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
Cash Flow | ||||||
| Free Cash Flow | -60.33M | -77.17M | -63.15M | -52.33M | -46.43M | -36.11M |
| Operating Cash Flow | -60.33M | -77.16M | -62.60M | -52.07M | -45.86M | -33.68M |
| Investing Cash Flow | 80.00K | 5.00K | -532.00K | -267.00K | -576.00K | -2.43M |
| Financing Cash Flow | 28.06M | 34.21M | 47.88M | 100.97M | 55.00K | 100.97M |
Jasper Therapeutics Technical Analysis
Negative
0.72
Price Trends
0.64
Negative
0.61
Negative
0.89
Negative
Market Momentum
-0.04
Positive
38.59
Neutral
27.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.64, and below the 200-day MA of 0.89, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.59 is Neutral, neither overbought nor oversold. The STOCH value of 27.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.
Jasper Therapeutics Risk Analysis
Jasper Therapeutics disclosed 90 risk factors in its most recent earnings report. Jasper Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jasper Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $16.63M | -0.32 | -618.87% | ― | ― | 73.74% | |
48 Neutral | $42.03M | -0.39 | -74.90% | <0.01% | ― | 44.73% | |
47 Neutral | $27.26M | -0.63 | -202.14% | ― | ― | 73.69% | |
46 Neutral | $106.24M | -0.85 | -320.60% | ― | -10.30% | 84.17% | |
43 Neutral | $21.49M | -3.00 | 19.96% | ― | ― | ― | |
41 Neutral | $320.72M | -1.96 | -53.86% | ― | ― | -7.24% |
* Healthcare Sector Average
JSPR
Jasper Therapeutics
0.50
-1.84
-78.76%
CVM
Cel-Sci
1.61
-7.38
-82.09%
BYSI
Beyondspring
0.45
-1.58
-77.97%
CBUS
Cibus
1.40
-0.18
-11.39%
ACET
Adicet Bio
4.28
-9.50
-68.94%
ARTV
Artiva Biotherapeutics, Inc.
6.20
1.36
28.10%
Jasper Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Jasper Therapeutics advances Phase 2 renal basket study
Positive
Oct 15, 2026
On October 15, 2026, Jasper Therapeutics reported that it had completed enrollment of the IgA nephropathy cohort in a Phase 2 renal basket study of vensobafusp alfa in China. The first stage enrolled 18 IgAN patients across three dosing regimens t...
Business Operations and Strategy
Jasper Therapeutics Launches Tender Offer to Retire Warrants
Positive
Oct 7, 2026
On October 7, 2026, Jasper Therapeutics launched a cash tender offer for any and all of the 12,345,707 warrants issued in its September 18, 2025 underwritten public offering, paying $0.324 per warrant. Each warrant entitles the holder to buy one s...
Business Operations and StrategyShareholder MeetingsStock Split
Jasper Therapeutics Stockholders Approve Capital Structure Flexibility
Neutral
Oct 5, 2026
On September 30, 2026, Jasper Therapeutics, Inc. held a special meeting of stockholders at which approximately 65% of outstanding common shares were represented, and investors approved all proposals on the agenda concerning the company’s cap...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Jasper Therapeutics Appoints Interim Finance and Governance Leaders
Neutral
Sep 28, 2026
On September 23, 2026, Jasper Therapeutics’ Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary, Herb Cross, submitted his resignation effective October 9, 2026, to pursue other professi...
Executive/Board ChangesShareholder Meetings
Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan
Positive
Aug 3, 2026
On July 31, 2026, Jasper Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, with approximately 75% of eligible voting common stock represented virtually or by proxy. Stockholders elected two Class II directors, Judith Shizuru and Tom...
Business Operations and StrategyM&A Transactions
Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition, Issues CVRs
Positive
Jul 31, 2026
On July 16, 2026, Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals and set that closing date as the record date for issuing contractual contingent value rights to holders of its common stock. Each pre-closing shareholder recei...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.